Biotech company BioVersys is first Swiss IPO of 2025
Biotech company Bioversys is first IPO in 2025
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Biotech company BioVersys is first Swiss IPO of 2025
The Basel-based biotech company BioVersys made the first initial public offering (IPO) of the year in Switzerland on Friday. Shares started trading on the SIX Swiss Exchange at CHF36.50 ($40.25).
This content was published on
2 minutes
Keystone-SDA
Deutsch
de
Biotechunternehmen Bioversys ist erster Börsengang 2025
Original
This gave the company a market capitalisation of CHF216 million. The share price then fell slightly and was still quoted at CHF36 in the first hour of trading. A total of around 47,000 shares had been traded by then.
BioVersys has offered just under 2.1 million shares in the company as part of the bookbuilding process. In addition, there may be an over-allotment option of just under 139,000 shares.
Focus on antibiotics
The biotech company will thus generate proceeds of CHF80 million from the IPO. According to management, the money will primarily be used to finance the main product BV100.
The Basel-based company focuses on the treatment of life-threatening infectious diseases. It concentrates on antibiotics.
BV100 is reportedly used to treat hospital infections with carbapenem-resistant Acinetobacter baumannii (CRAB). The money will be used to take the antibiotic through clinical phase III, the company explained.
‘Milestone’
“Today marks an important milestone for BioVersys as we take the next step in our growth strategy,” said CEO Marc Gitzinger in a statement issued by the SIX Swiss Exchange.
Existing shareholders had already committed in advance to subscribe for shares. The Glaxo Group had invested CHF3.5 million in the offer. The AMR Action Fund also bought shares offered by the company.
The head of the Swiss stock exchange, Bjørn Sibbern, is also pleased about the IPO. “It is a good example of how a biotech company prefers an IPO on SIX Swiss Exchange to an IPO overseas,” he said.
Translated from German by DeepL/ts
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Swiss health office turns to Bluesky against backdrop of US censorship
This content was published on
The Swiss Federal Office of Public Health (FOPH) has joined the Bluesky social network, while US President Donald Trump works with X owner Elon Musk to censor content on official US websites.
Much more spent on Swiss motorway vote campaigns than budgeted
This content was published on
Opponents and supporters of motorway expansion spent over CHF10 million ($11 million) on their campaigns, around a third more than announced in November.
Swiss researchers monitor animal populations with AI microphone
This content was published on
Researchers in Lausanne are using an intelligent microphone to make the animal world audible. The microphone automatically records animal sounds over large areas and analyses them using AI.
Three employees of Swiss aid organisation killed in DRC
This content was published on
Three employees of the Swiss Protestant Reformed Church (Heks) have been killed in an attack in the Democratic Republic of Congo (DRC). They were on a humanitarian mission in the crisis region.
This content was published on
All our waters today are pure at source," Muriel Lienau, general manager of Nestlé Waters, told AFP after press revelations.
Switzerland concerned about impact of US withdrawal from WHO
This content was published on
Switzerland has expressed concern about the loss of American experts and the freezing of contracts due to the announced withdrawal of the US from the World Health Organization (WHO).
Rhine Falls is most rated Swiss location on Google Maps
This content was published on
The Rhine Falls in Schaffhausen, northern Switzerland, with more than 75,000 ratings, is the Swiss place most reviewed by Google Maps users.
Asian investors sue Switzerland over Credit Suisse bond losses
This content was published on
More than 500 investors from Singapore, Japan and Hong Kong have launched claims against Switzerland in relation to AT1 bonds.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.